Skip to main page content
U.S. flag

An official website of the United States government

Dot gov

The .gov means it’s official.
Federal government websites often end in .gov or .mil. Before sharing sensitive information, make sure you’re on a federal government site.

Https

The site is secure.
The https:// ensures that you are connecting to the official website and that any information you provide is encrypted and transmitted securely.

Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation
. 2021 Sep;56(9):2280-2283.
doi: 10.1038/s41409-021-01320-y. Epub 2021 May 7.

Pre-existing immune checkpoints activation predicts relapse after allogeneic stem cell transplantation in lymphoma

Enrico Derenzini  1   2 , Valentina Tabanelli  3 , Simona Sammassimo  4 , Saveria Mazzara  3 , Giovanna Motta  3 , Federica Melle  3 , Anna Vanazzi  4 , Angelica Calleri  3 , Stefano Fiori  3 , Maria Chiara Finazzi  5 , Maria Chiara Barbanti  5 , Safaa Ramadan  4 , Sara Gandini  6 , Rocco Pastano  4 , Alessandro Rambaldi  5   7 , Stefano Pileri  3 , Corrado Tarella  8   9
Affiliations

Pre-existing immune checkpoints activation predicts relapse after allogeneic stem cell transplantation in lymphoma

Enrico Derenzini et al. Bone Marrow Transplant. 2021 Sep.
No abstract available

PubMed Disclaimer

References

    1. Nguyen LT, Ohashi PS. Clinical blockade of PD1 and LAG3—potential mechanisms of action. Nat Rev Immunol. 2015;15:45–56. - DOI
    1. Armand P, Shipp MA, Ribrag V, Michot JM, Zinzani PL, Kuruvilla J, et al. Programmed death-1 blockade with pembrolizumab in patients with classical Hodgkin lymphoma after brentuximab vedotin failure. J Clin Oncol. 2016;34:3733–9. - DOI
    1. Younes A, Santoro A, Shipp M, Zinzani PL, Timmerman JM, Ansell S, et al. Nivolumab for classical Hodgkin’s lymphoma after failure of both autologous stem-cell transplantation and brentuximab vedotin: a multicentre, multicohort, single-arm phase 2 trial. Lancet Oncol. 2016;17:1283–94. - DOI
    1. Haverkos BM, Abbott D, Hamadani M, Armand P, Flowers ME, Merryman R, et al. PD-1 blockade for relapsed lymphoma post-allogeneic hematopoietic cell transplant: high response rate but frequent GVHD. Blood 2017;130:221–8. - DOI
    1. Davids MS, Kim HT, Bachireddy P, Costello C, Liguori R, Savell A, et al. Ipilimumab for patients with relapse after allogeneic transplantation. N. Engl J Med. 2016;375:143–53. - DOI

Publication types

LinkOut - more resources